The T-allele of TCF7L2 rs7903146 associates with a reduced compensation of insulin secretion for insulin resistance induced by nine days of bed rest

Running title: bed rest impact in carriers of TCF7L2 T-allele

Amra C. Alibegovic1, Mette P. Sonne5,6, Lise Højbjerg5,6, Torben Hansen2,3, Oluf Pedersen2,4, Gerrit van Hall5,7, Jens J. Holst6, Bente Stallknecht5,6, Flemming Dela5,6 and Allan Vaag1

1Steno Diabetes Centre, Gentofte, Denmark;
2Hagedorn Research Institute, Gentofte, Denmark, Institute of Biomedical Science, University of Copenhagen, Denmark, 3Faculty of Health Science, University of Southern Denmark and
4Faculty of Health Science, University of Aarhus, Denmark;
5Center for Healthy Ageing; 6Department of Biomedical Sciences, Faculty of Health Sciences, University of Copenhagen, Copenhagen, Denmark;
7Metabolic Mass-Spectrometry Facility, Rigshospitalet; Copenhagen University Hospital, Copenhagen, Denmark

Corresponding author:
Amra Ciric Alibegovic, MD
E-mail: aagv@steno.dk

Submitted 21 June 2009 and accepted 17 January 2010.

This is an uncopyedited electronic version of an article accepted for publication in Diabetes. The American Diabetes Association, publisher of Diabetes, is not responsible for any errors or omissions in this version of the manuscript or any version derived from it by third parties. The definitive publisher-authenticated version will be available in a future issue of Diabetes in print and online at http://diabetes.diabetesjournals.org.
Objective: The aim of this study was to determine whether the type 2 diabetes (T2D) associated T-allele of TCF7L2 rs7903146 associates with impaired insulin secretion to compensate for insulin resistance induced by bed rest.

Research Design and Methods: 38 healthy young Caucasian men were studied before and after bed rest using the hyperinsulinemic euglycemic clamp technique combined with indirect calorimetry preceded by an intravenous glucose tolerance test. The TCF7L2 rs7903146 was genotyped using allelic discrimination performed with an ABI 7900 system. The genetic analyses were done assuming a dominant model of inheritance.

Results: The first phase insulin response (FPIR) was significantly lower in carriers of the T-allele compared to carriers of the CC genotype before bed rest with and without correction for insulin resistance. The incremental rise of FPIR in response to insulin resistance induced by bed rest was lower in carriers of the T-allele ($P < 0.001$). Fasting plasma glucagon levels were significantly lower in carriers of the T-allele before and after bed rest. While carriers of the CC genotype developed increased hepatic insulin resistance, the TCF7L2 rs7903146 did not influence peripheral insulin action or the rate of lipolysis before or after bed rest.

Conclusions: Healthy carriers of the T-allele of TCF7L2 rs7903146 exhibit a diminished increase of insulin secretion in response to intravenous glucose to compensate for insulin resistance as induced by bed rest. Reduced paracrine glucagon stimulation may contribute to the impairment of β-cell function in carriers the TCF7L2 rs7903146 T-allele associated with increased risk of T2D.
T2D is caused by a complicated interplay between genetic and environmental factors acting on glucose and fat metabolism involving multiple defects of peripheral (muscle) and hepatic insulin action, insulin secretion, adipose tissue metabolism, whole body lipolysis, and possibly a range of additional metabolic defects in a number of other organs (1). Nevertheless, the manifestation of overt diabetes is a direct result of a metabolic state when pancreatic insulin secretion fails to compensate for insulin resistance.

The transcription factor 7-like 2 (TCF7L2) is a member of the T-cell transcription factor family which through regulation of cell proliferation and differentiation plays a critical role in the WNT signalling pathway (2). During embryonic growth in humans WNT signalling is required for the development and maturation of the pancreas including the islets of Langerhans (3). Recent studies have established TCF7L2 as the so far most significant T2D susceptibility gene (4-9). Thus, each T-allele of TCF7L2 rs7903146 increases T2D risk with an odds ratio of 1.37 even in the presence of a reduced body weight (4;6;10-14). The diabetogenic impact of the rs7903146 TCF7L2 variant or its linked causative variant appears to be mediated through decreased insulin secretion, and/or through defects in insulin processing, reduced effects of Glucagon-like peptide 1 (GLP-1) and increased hepatic glucose production (15-17).

Recently, Wegner et al. showed that the T-allele of TCF7L2 rs7903146 risk associated with an absolute and relative impairment of insulin secretion and with increased peripheral insulin sensitivity in elderly twins (18). Similarly, in a study of young and healthy glucose tolerant men, Pilgaard et al. demonstrated that the same variant associated with reduced insulin secretion relative to the glucose level during a mixed meal test and with an elevated rate of endogenous glucose production in the basal state as well as following in vivo insulin infusion (19).

In the present study we performed detailed metabolic characterisation of young healthy men to determine whether the T-allele of TCF7L2 rs7903146 is associated with impaired insulin secretion and/or insulin action in response to nine days of bed rest.

**RESEARCH DESIGN AND METHODS**

**Subjects:** 38 healthy young Caucasian men completed the study. Subjects were recruited from a cohort of young men with low birth weight (LBW) and normal birth weight via the Danish National Birth Registry. LBW was defined as the lowest 10 percentile and the controls were recruited from the 50-75 birth weight percentiles. 21 subjects were carriers of the T-allele of TCF7L2 rs7903146 (combined TT and CT alleles) and 17 subjects were carriers of the CC genotype. The number of LBW subjects was 11 in the group of carriers of the T-allele and 10 in carriers of the CC genotype, respectively. No impact of – or association between – birth weight and genotype were observed.

**Ethical approval:** The study was approved by the regional ethical committee (ref. # 01-262546) and all procedures were performed in accordance with the guidelines of the Declaration of Helsinki. Informed written consent was obtained from all the subjects before participation.

**Experimental protocol Control period:** Subjects were requested to abstain from strenuous physical activity and from consuming alcohol three days prior to examination. To ensure standardized conditions, all subjects were provided with an isocaloric nutritionally standardized diet three days prior to the first study day and during the
bed rest with adjusted caloric content to ensure weight stability. Body composition as well as fat free mass and fat mass was determined by DXA scan as previously described (20).

**Bed rest challenge:** All subjects were admitted to Steno Diabetes Center for nine days and were not permitted to deviate from a half-recumbent position during this period. Toilet visits were limited to 15 minutes per day. Study subjects were allowed to use a lab top, watch television and to read in the bed. Blood samples for measurements of fasting plasma insulin and fasting plasma C-peptide were taken at the 1st, 2nd, 3rd, 5th, 7th and 9th day of bed rest. Body weight of all subjects was recorded every morning throughout the intervention to ensure weight stability.

**Hyperinsulinemic euglycemic clamp combined with stable isotope infusion and indirect calorimetry:** Identical in vivo experiments were performed before and after the bed rest intervention as previously described in details (20). A schematic presentation of the experimental day is presented in Fig. 1.

**Analytical procedures.** Blood samples for plasma insulin, plasma C-peptide and blood samples for glucose and glycerol enrichment determination were performed as previously described (20). Glucagon concentrations were measured after extraction of plasma with 70% ethanol (vol./vol., final concentration). The antibody employed was directed against the C-terminus of the glucagon molecule and therefore mainly measured glucagon of pancreatic origin (21). Standards were human glucagon and tracer was monoiodinated human glucagon (both gifts from NovoNordisk, Bagsværd). Sensitivity and detection limit is below 1 pmol/l, intrassay coefficient of variation below 6 % at 20-30 pmol/l, and recovery of standard, added to plasma before extraction, about 100 % when corrected for losses inherent in the plasma extraction procedure. Plasma triglyceride concentration was determined with Triglyceride GPO-PAP (Roche Diagnostics, Mannheim, Germany). Total and HDL-cholesterol were analyzed with an enzymatic colorimetric test (Roche Diagnostics). LDL-cholesterol was calculated from the Friedewald formula (22) and VLDL-cholesterol was calculated as plasma triglyceride divided by 2.2. Glucose and glycerol enrichment samples were measured as previously described in details (23;24).

**Genotyping:** Genomic DNA was extracted from blood using conventional methods. TCF7L2 rs7903146 was genotyped using allelic discrimination performed with an ABI 7900 system (KBioscience, Herts, UK) as previously described (18). The overall genotyping success rate was more than 96%.

**Calculations: Intra venous glucose tolerance test (β-cell test):** The incremental first phase insulin response (FPIR) during the IVGTT was calculated as the incremental area under the curve (AUC) \([\text{AUC}_{\text{insulin (0-10 min)}} - \text{AUC}_{\text{basal (ins 0 * 10)}}]\). The second phase insulin secretion during IVGTT was calculated as \(\text{AUC}_{\text{insulin (10-30 min)}}\). The total area under the curve was calculated using a trapezoidal method for glucose and insulin during 30 min as \(\frac{\text{AUC}_{\text{insulin (0-30 min)}}}{\text{AUC}_{\text{glucose (0-30 min)}}}\).

The disposition index expressing the inverse hyperbolic relationship between insulin secretion and insulin action is an estimate of the “true” in vivo pancreatic beta cell insulin secretion capacity. The peripheral disposition index (\(D_i-\text{peripheral}\)) was calculated as [FPIR * M] and the hepatic disposition index (\(D_i-\text{hepatic}\)) as [FPIR / HIR]. The hepatic insulin resistance index (HIR) was calculated as the product of fasting plasma insulin concentration and the basal hepatic glucose production as previously described (25).

**Hyperinsulinemic euglycemic clamp and indirect calorimetry:** Glucose infusion rates were calculated as the mean of steady state glucose infusion rates during the
predefined insulin-stimulated steady-state period from 330 to 360 minutes. Basal and insulin-stimulated rates of glucose and lipid oxidation as well as non-oxidative glucose oxidation rate were calculated according to the methods of Frayn (26).

**Stable isotope tracer calculations:** Tracer-to-tracee ratios (TTR) for both glucose and glycerol were calculated as previously described (20).

**Statistics:** Statistical analysis was performed with the SAS statistical analysis package (version 9.1; SAS Institute, Cary, NC, USA). Due to the low number of subjects, TT and CT genotypes were pooled and a dominant model was applied. The selection of the dominant model for this locus is arbitrary and one of convenience, as most of the evidence published on rs7903146 indicates an additive model of risk transmission. One-way ANOVA analyses were performed to test for differences between groups before and after bed rest. The paired-sample t-test was used to detect statistically significant differences within groups in response to bed rest. The Kolmogorov-Smirnov test was used to test whether data were normally distributed and whether logarithmic transformation of non-normally distributed data rendered them normally distributed. P-values of < 0.05 were considered as significant and data are presented as means ± standard deviations (SDs). In a post hoc power calculation with the first-phase insulin secretion data as the endpoint, we had an 80% chance of detecting differences between carriers of the T-allele and carriers of the CC genotype of approximately 66% after bed rest with a group 1 size of 21 subjects and a group 2 size of 17 subjects.

**RESULTS**

**Clinical characteristics of study participants:** As presented in Table I, we found no significant differences in age, weight, height, systolic and diastolic blood pressure, maximal oxygen uptake (VO$_{2\text{max}}$), total fat mass, fat percentage, trunk fat mass/total fat mass ratio, leg fat mass/total fat mass ratio, plasma triglycerides, plasma cholesterol as well as plasma concentration of others lipoproteins between TT/CT carriers and CC carriers prior to bed rest. We demonstrated a significant decrease in VO$_{2\text{max}}$, plasma total cholesterol and plasma HDL concentrations in carriers of the CC but not the TT/CT genotypes following nine days of bed rest. However, we observed a similar BMI in carriers of the T-allele compared to carriers of the CC genotype before and after bed rest.

No differences were observed between TT/CT and CC carriers with regard to age, weight, height, systolic and diastolic blood pressure, VO$_{2\text{max}}$, total fat mass, fat percentage, trunk fat mass/total fat mass ratio, leg fat mass/total fat mass or plasma concentrations of triglycerides, total cholesterol, LDL and VLDL after bed rest.

**Impact of the T-allele of rs7903146 on insulin secretion during IVGTT:** As presented in Table II, first phase insulin secretion (FPIR) was significantly diminished in carriers of the T-allele compared to carriers of the CC genotype before as well as after nine days of bed rest. The decreased FPIR in carriers of the T-allele remained significant after correction for BMI before ($P = 0.01$) and after bed rest ($P = 0.0001$). We showed a significantly lower insulin secretion during the time period from 10 to 30 min after glucose infusion (i.e. AUC$_{10-30\text{ min}}$), to some extent reflecting a reduced late or second phase insulin secretion in carriers of the T-allele compared to carriers of the CC genotype after bed rest ($P<0.001$). The estimates of second phase insulin secretion data are included also in Table II. The area under the curve during IVGTT, AUC$_{0-10\text{ min}}$, for plasma insulin and C-peptide were similar in TT/CT and CC genotype carriers before bed rest (Fig. 2). However, we unmasked a
significantly lower the area under the curve during IVGTT, AUC$_{0-10}$ min, for plasma insulin and C-peptide in carriers of the T-allele compared to carriers of the CC genotype after bed rest (Fig 3).

Fasting plasma insulin and C-peptide levels were significantly decreased in the TT/CT genotype as compared with the CC genotype carriers on day 9 during the bed rest experiments (Fig. 4). Furthermore, carriers of the T allele had significantly reduced fasting plasma glucagon concentrations in the basal state before and after bed rest compared to carriers of the CC allele as presented in Table II. FPIR increased significantly in response to bed rest in both groups but the increment in FPIR was significantly lower in carriers of the T-allele compared to carriers of the CC genotype (P<0.001).

The total area under the curve, AUC$_{total}$, was significantly lower in carriers of the T-allele compared to carriers of the CC genotype after bed rest. Furthermore, in response to bed rest we demonstrated a significant increase in AUC$_{total}$ in CC carriers, but not in carriers of the risk T-allele (Table II).

**Impact of the T-allele of rs7903146 on hepatic and peripheral insulin sensitivity:**

As seen in Table II, fasting plasma insulin and glucose concentrations were similar between genotypes before as well as after bed rest. The peripheral (muscle) insulin action, measured by the hyperinsulinemic euglycemic clamp, was significantly decreased in response to bed rest without differences between the genotype groups. Despite decreased peripheral insulin action in all subjects in response to bed rest, carriers of the T-allele tended to be more insulin sensitive after bed rest as determined by the Homeostasis-Model-Assessment (HOMA) index. Furthermore, carriers of the T allele demonstrated a similar decrease in the M-value as measured by the hyperinsulinemic euglycemic clamp technique compared to carriers of the CC genotype.

Estimates of insulin secretion adjusted for peripheral insulin sensitivity, i.e. peripheral and hepatic disposition index, were lower in carriers of the T-allele before bed rest. Notably, the peripheral disposition index, but not the hepatic disposition index, was also significantly decreased in carriers of the T-allele compared to carriers of the CC genotype after bed rest.

As presented in Table III, carriers of the CC genotype, but not carriers of the T-allele, developed a significant increase in the hepatic insulin resistance index ($P<0.01$) in response to bed rest. However, we found no significant differences in rate of appearance of glucose and glycerol between genotype groups neither before nor after bed rest.

**Impact of the T-allele of rs7903146 T-allele on gaseous exchange measurements:** Basal glucose oxidation increased and basal fat oxidation decreased significantly in response to bed rest in the both genotype groups as presented in Table II. The glucose and fat oxidation rates during insulin infusion were not significantly affected by bed rest in any of the genotype groups.

The insulin stimulated non-oxidative glucose metabolism decreased significantly in carriers of the CC genotype as well as in carriers of the T-allele (all $P < 0.01$) with no differences between the groups before and after bed rest.

**DISCUSSION**

Previous studies demonstrated that the mechanisms by which the T-allele of TCF7L2 rs7903146 is a marker for increased risk of T2D most probable involve impairment at various steps of insulin biosynthesis and release (27-29). The most important finding from the present study is that young healthy carriers of the risk T-allele exhibit a diminished compensatory increase in glucose
stimulated plasma insulin and plasma C-peptide secretion during nine days of bed rest indicating a greater vulnerability to bed rest compared to carriers of the low risk CC genotype.

Previous results from the Diabetes Prevention Program as well as from the Finnish Diabetes Prevention Study suggested an increased risk of type 2 diabetes in less physically active carriers of the TCF7L2 rs7903146 (28;30). In this study, we document that this significant adverse gene-environment interaction mechanistically may be caused by an inability of the carriers of the T-allele of TCF7L2 rs7903146 to increase insulin secretion to compensate for insulin resistance when exposed to physical inactivity. The extent to which other lifestyle factors including diet, sleep deprivation, stress etc may interact with distinct susceptibility genotypes increasing the risk of developing overt type 2 diabetes remain to be documented.

It is generally recognized that in vivo insulin secretion should be corrected for the ambient degree of whole body insulin sensitivity and expressed as a disposition index taking into account the ability of the normal pancreatic β-cell to adapt insulin secretion to the level of insulin sensitivity (31). Lyssenko et al. demonstrated reduced insulin secretion after correction for the degree of insulin action in response to oral glucose ingestion in glucose tolerant carriers of the T-allele of TCF7L2 rs7903146, while no difference in the absolute insulin secretion capacity (area under the curve, AUC insulin OGGT and AUC insulin IVGTT) was seen between different genotype carriers (29). In addition, in glucose tolerant individuals no difference in arginin stimulated insulin secretion was demonstrated between carriers of the CC genotype and carriers of the T-allele (29).

In the present extensive metabolic study we unmasked a disproportionately reduced insulin secretion in response to an intravenous glucose infusion after bed rest in young healthy carriers of the T-allele of TCF7L2 rs7903146 compared to carriers of the CC genotype (Fig. 3). Furthermore, we demonstrated an impaired insulin secretion in carriers of the T-allele when corrected for the ambient level of peripheral insulin sensitivity before and in particular after bed rest (Table II). Our finding provides direct evidence for an impaired pancreatic insulin secretion relative to the level of peripheral insulin resistance in young healthy carriers of the risk T-allele. Importantly, we show that carriers of the T-allele of TCF7L2 rs7903146 were unable to increase pancreatic insulin secretion to compensate appropriately for peripheral insulin resistance as induced by physical inactivity providing proof-of-concept for an adverse interaction between genotype and an important lifestyle determinant such as physical inactivity on risk of developing T2D. Furthermore, we confirmed our previous finding of significantly lower fasting plasma glucagon levels in carriers of the T allele of TCF7L2 rs7903146 prior to and after bed rest (19). As discussed in this paper by Pilgaard et al (19), this may be explained by reduced expression of proglucagon in the alpha cells or by altered post translational processing of proglucagon to glucagon. Importantly, our confirmation of reduced plasma glucagon in the context of a documented reduced insulin secretion in response to intravenous glucose support the idea of impaired paracrine glucagon stimulation playing a significant role in the development of impaired beta cell function in carriers of the T-allele of TCF7L2 rs7903146.

Carriers of the T-allele of TCF7L2 have an increased risk of non alcoholic liver steatosis and fibrosis (32) and other studies report that the T allele of TCF7L2 is associated with an increased rate of endogenous glucose production in the basal state and during insulin infusion (18;19;29). In this study, the slightly elevated rate of
hepatic glucose production in carriers of the T-allele \( (P = 0.10) \) at baseline did not reach statistical significance. Furthermore, carriers of the T-allele exhibited a significantly - and paradoxically - decreased hepatic insulin resistance index compared to carriers of the CC genotype after bed rest (Table III). This interesting reversal of phenotype according to hepatic glucose production and hepatic insulin sensitivity is most likely to be explained by the clear separation of the fasting plasma insulin and C-peptide levels in the two study groups with increasing duration of bed rest (Fig. 4). These curves illustrate the unmasking effects of bed rest on a significant T2D abnormality of reduced insulin secretion even in the fasting state in carriers of the T-allele. In that situation, the apparently increased hepatic insulin sensitivity in the carriers of the T-allele is due only to reduced fasting plasma insulin levels, and the question may therefore be raised to which extent this calculated sensitivity index is a true biological phenomenon or a result of an inadequate estimate of hepatic insulin sensitivity calculated from peripheral and not portal plasma insulin levels. However, the parallel differences of circulating plasma insulin as well as plasma C-peptide levels suggest that this is not only a result of altered hepatic insulin extraction. Although the lower fasting plasma glucagon levels may contribute to the lower hepatic insulin resistance in carriers of the T-allele after bed rest, this is unlikely to be the full explanation. Thus, in agreement with the data from Pilgaard et al. (19), fasting plasma glucagon levels were reduced to the same extent in carriers of the T-allele prior to bed rest when hepatic insulin resistance was not reduced in these subjects.

Wegner et al. demonstrated a reduced insulin secretion in response to intravenous glucose in the absolute sense as well as an increased peripheral insulin sensitivity with no difference in the peripheral disposition index in elderly carriers of the T-allele of TCF7L2 rs7903146 in a twin study (18). We speculated that the relatively increased peripheral insulin action in the elderly non-diabetic twins carrying the T-allele might be the result of an increase of peripheral (muscle) insulin action to compensate for a primary and long lasting genuine impairment of insulin secretion (18). Along with this line of thinking, the relatively decreased HOMA as well as peripheral insulin action after bed rest in carriers of the T-allele of TCF7L2 rs7903146 may not be unexpected (Table II). Although the conventional view is that the pancreatic insulin secretion senses and compensates for the ambient degree of both hepatic and peripheral insulin action, the present results support the view that the plasma insulin level \textit{per se} is playing a significant role for the ambient degree of insulin action, and that the compensatory interaction between insulin action and insulin secretion might work in both ways to preserve the metabolic homeostasis. In support of this view, we recently demonstrated that increased circulating insulin levels precedes the development of peripheral insulin resistance in response to short term high fat feeding \textit{in vivo} in young and healthy men (33).

When including hepatic insulin action in the calculation of insulin secretion relative to insulin action, we found a lower insulin secretion hepatic disposition index in carriers of the T-allele prior to, but not after, bed rest. The similar level of insulin secretion hepatic disposition index after bed rest between carriers of different genotypes of TCF7L2 is likely to be caused by the elevated hepatic insulin resistance in carriers of the CC genotype in response to bed rest.

Previous studies suggested that the decreased insulin secretion in carriers of the T-allele might be explained by a reduced gut hormone incretin effect, and more specifically a reduced insulinotrophic effect of GLP-1 (19;34;35). The finding of impaired insulin secretion in response to an intravenous
glucose tolerance test in carriers of the T-allele, bypassing the impact of gut incretin hormones, does not support the view that an impaired incretin effect may fully explain the decreased insulin secretion in carriers of the T-allele. Thus, the accumulated physiological evidence suggests that carriers of the T-allele of TCF7L2 rs7903146 exhibit reduced insulin secretion as a result of a combination of impaired incretin effect and impaired intrinsic pancreatic β-cell function and/or β-cell mass. To this end, impaired paracrine effect of glucagon to stimulate insulin secretion may count as a part of the intrinsic pancreatic beta cell dysfunction.

Correction for BMI being non-significantly lower in carriers of the at risk T-allele of TCF7L2 rs7903146 did not change the finding of a significantly reduced insulin secretion as well as a higher in vivo insulin action in these subjects as compared with carriers of the CC-genotype after bed rest. In previous studies from our group we also found trends toward a lower BMI in carriers of the T-allele, which in turn theoretically could be due to reduced insulin secretion (18;19).

The detailed and significant number of metabolic parameters measured in the study subjects were not corrected for multiple comparisons, which would have resulted in loss of statistical power and less significant differences between the two groups. The rationale for not correcting for multiple comparisons includes the fact that previous studies have suggested different degrees of evidence for the different defects of metabolism with defective insulin secretion, increased hepatic glucose production and reduced plasma glucagon levels being some of the most prominent defects previously reported in carriers of the T-allele of the TCF7L2 rs7903146 (19;28-30). Indeed, these defects were the ones most likely to become unmasked by exposure to insulin resistance as induced by physical inactivity.

In another recent publication from our group, we reported that insulin resistant first degree relatives (FDR) of patients with Type 2 diabetes were more susceptible to develop hepatic insulin resistance when exposed to bed rest as compared with controls without FDR (20). To avoid further genetic admixture of type 2 diabetes susceptibility genes in this study, FDR subjects were not included. However, it is interesting that the currently most important type 2 diabetes susceptibility gene TCF7L2 is indeed very common among subjects without a genetic predisposition to diabetes, and furthermore that the phenotypic appearance including the response to bed rest differs markedly between FDR subjects and carriers of the most significant known susceptibility gene with the latter representing a primary defective pancreatic insulin secretion. This suggest that other more significant - and currently unknown - insulin resistance genes are involved, or alternatively that environmental factors clustering in families of patients with type 2 diabetes plays a more significant role in the phenotypic appearance.

In conclusion, young healthy men who are carriers of the T2D-associated T-allele of TCF7L2 rs7903146 and who are exposed to nine days of physical inactivity develop an insulin response to intravenous glucose which is insufficient to compensate for the induced insulin resistance.

ACKNOWLEDGEMENTS

The data presented in this manuscript are a part of a larger study on the influence of physical inactivity in young healthy subjects with and without risk of later development of T2D including subjects with low birth weight and first degree relatives of patients with T2D. Parts of the study have been published elsewhere (20) This work is initiated and funded by the European Union Framework VI; EXGENESIS project.
The authors thank Lars Sander Koch, Marianne Modest and Nina Pluszek for eminent and dedicated technical assistance during experiments and when analyzing samples. The authors wish to express our gratitude to all the young men who participated in this study.

**Funding:** This study was funded by the EU 6th Framework EXGENESIS grant and supported by the Danish Strategic Research Council. A. C. Alibegovic was granted PhD scholarships from Academy of Muscle Biology, Exercise and from Health Research and The Ministry of Science, Technology and Innovation, Copenhagen, Denmark.

**Potential conflicts of interests:** All authors declare that there is no duality of interest associated with the study.

---

**FIGURE LEGENDS**

**Fig. 1**
Schematic presentation of the experimental day(s); Whole body glucose metabolism was measured by a hyperinsulinemic euglycemic clamp technique. Steady-state measurements of plasma glucose and plasma glycerol enrichments were performed during the basal period (before the insulin stimulation) to determine hepatic glucose production and whole body lipolysis rate. Arrows show points for collecting of blood samples for basal state determination of stable isotope kinetics.

**Fig. 2**
AUC$_{0-10\text{min}}$ for plasma insulin during IVGTT before bed rest; Data are presented as mean ± SEM in carriers of the risk T-allele (black circles) and carriers of low risk CC genotype (white circles) and AUC$_{0-10\text{min}}$ for plasma C-peptide during IVGTT before bed rest; Data are presented as mean ± SEM in carriers of the risk T-allele (black triangles) and carriers of low risk CC genotype (white triangles).

**Fig. 3**
AUC$_{0-10\text{min}}$ for plasma insulin during IVGTT after bed rest; Data are presented as mean ± SEM in carriers of the risk T-allele (black circles) and carriers of low risk CC genotype (white circles) and AUC$_{0-10\text{min}}$ for plasma C-peptide during IVGTT after bed rest; Data are presented as mean ± SEM in carriers of the risk T-allele (black triangles) and carriers of low risk CC genotype (white triangles). * $P<0.05$; ** $P<0.01$.

**Fig. 4**
Plasma insulin concentration during nine days of bed rest; * $P<0.05$; Data are presented as mean ± SEM in carriers of the risk T-allele (white triangles) and carriers of low risk CC genotype (black triangles). P$_{\text{ANOVA day1}}=0.93$; P$_{\text{day2}}=0.41$; P$_{\text{day3}}=0.75$; P$_{\text{day5}}=0.15$; P$_{\text{day7}}=0.24$; P$_{\text{day9}}=0.02$. Plasma C-peptide concentration during nine days of bed rest; * $P<0.05$; Data are presented as mean ± SEM in carriers of the risk T-allele (white circles) and carriers of low risk CC genotype (black circles). P$_{\text{ANOVA day1}}=0.63$; P$_{\text{day2}}=0.24$; P$_{\text{day3}}=0.39$; P$_{\text{day5}}=0.14$; P$_{\text{day7}}=0.39$; P$_{\text{day9}}=0.02$. 
REFERENCES
bed rest impact in carriers of TCF7L2 T-allele


### Table I
Clinical characteristic of male study participants according to TCF7L2 rs7903146 genotype before and after bed rest

<table>
<thead>
<tr>
<th>rs7903146</th>
<th>Before bed rest</th>
<th>After bed rest</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>TT/CT</td>
<td>CC</td>
</tr>
<tr>
<td>Number (n)</td>
<td>21</td>
<td>17</td>
</tr>
<tr>
<td>Age (years)</td>
<td>25.6 ± 2.0</td>
<td>25.2 ± 2</td>
</tr>
<tr>
<td>Weight (kg)</td>
<td>75.6 ± 11.7</td>
<td>82.4 ± 11.8</td>
</tr>
<tr>
<td>Height (m)</td>
<td>1.81 ± 0.06</td>
<td>1.82 ± 0.06</td>
</tr>
<tr>
<td>BMI (kg/m²)</td>
<td>23.0 ± 2.7</td>
<td>24.4 ± 3.1</td>
</tr>
<tr>
<td>VO₂max (ml/min/kg)</td>
<td>43.0 ± 6.8</td>
<td>43.7 ± 7.8</td>
</tr>
<tr>
<td>Systolic BP (mm Hg)</td>
<td>125 ± 10</td>
<td>129 ± 14</td>
</tr>
<tr>
<td>Diastolic BP (mm Hg)</td>
<td>69 ± 8</td>
<td>70 ± 10</td>
</tr>
<tr>
<td>W/H-ratio</td>
<td>0.85 ± 0.05</td>
<td>0.86 ± 0.05</td>
</tr>
<tr>
<td>Total FM (kg)</td>
<td>12.6 ± 6.6</td>
<td>16.7 ± 8.3</td>
</tr>
<tr>
<td>Whole-body fat percentage (%)</td>
<td>16.5 ± 6.5</td>
<td>19.8 ± 7.5</td>
</tr>
<tr>
<td>Trunk FM /total FM ratio</td>
<td>0.50 ± 0.04</td>
<td>0.51 ± 0.04</td>
</tr>
<tr>
<td>Leg FM/total FM ratio</td>
<td>0.36 ± 0.04</td>
<td>0.35 ± 0.03</td>
</tr>
<tr>
<td>% trunk FM/leg FM ratio</td>
<td>1.41 ± 0.29</td>
<td>1.48 ± 0.30</td>
</tr>
<tr>
<td>Triglyceride (mmol/L)</td>
<td>0.9 ± 0.3</td>
<td>1.1 ± 0.9</td>
</tr>
<tr>
<td>Cholesterol (mmol/L)</td>
<td>3.8 ± 0.6</td>
<td>4.2 ± 1.0</td>
</tr>
<tr>
<td>HDL (mmol/L)</td>
<td>1.2 ± 0.2</td>
<td>1.3 ± 0.5</td>
</tr>
<tr>
<td>LDL (mmol/L)</td>
<td>2.1 ± 0.5</td>
<td>2.3 ± 1.0</td>
</tr>
<tr>
<td>VLDL (mmol/L)</td>
<td>0.4 ± 0.2</td>
<td>0.5 ± 0.4</td>
</tr>
</tbody>
</table>

Data are presented as mean ± SDs. * Significant difference before vs. after bed rest; P<0.05. Abbreviations: BP = blood pressure; BMI = body mass index; W/H ratio = waist to hip ratio; FM = fat mass; P = plasma; HDL = high density lipoprotein; LDL = low density lipoprotein; VLDL = very low density lipoprotein.

### Table II
Data on IVGTT, hyperinsulinemic euglycemic clamp and indirect calorimetry in male study participants according to TCF7L2 rs7903146 genotype before and after bed rest.

<table>
<thead>
<tr>
<th>rs7903146</th>
<th>Before bed rest</th>
<th>After bed rest</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>TT/CT</td>
<td>CC</td>
</tr>
<tr>
<td>Number (n)</td>
<td>21</td>
<td>17</td>
</tr>
<tr>
<td>P-glucose (mmol/L)</td>
<td>4.6 ± 0.4</td>
<td>4.6 ± 0.5</td>
</tr>
<tr>
<td>P-glucose (mmol/L)</td>
<td>5.0 ± 0.2</td>
<td>5.0 ± 0.2</td>
</tr>
<tr>
<td>P-insulin (pmol/L)</td>
<td>26 ± 14</td>
<td>33 ± 23</td>
</tr>
<tr>
<td>P-insulin (pmol/L)</td>
<td>745 ± 151</td>
<td>848 ± 258</td>
</tr>
<tr>
<td>P-glucagon (pmol/L)</td>
<td>6.7 ± 2.9</td>
<td>10.5 ± 4.3*</td>
</tr>
<tr>
<td>HOMA-IR* (10⁻⁶*mmol/L/mmol/L)</td>
<td>5.3 ± 3.2</td>
<td>6.9 ± 5.2</td>
</tr>
<tr>
<td>M-value (mg/min/kg FFM)</td>
<td>14.0 ± 1.9</td>
<td>14.0 ± 1.8</td>
</tr>
<tr>
<td>GOX (mg/min/kg FFM)</td>
<td>1.6 ± 4.4</td>
<td>1.4 ± 0.4</td>
</tr>
<tr>
<td>FOX (mg/min/kg FFM)</td>
<td>4.2 ± 0.6</td>
<td>4.3 ± 0.6</td>
</tr>
<tr>
<td>FOX (mg/min/kg FFM)</td>
<td>0.1 ± 0.2</td>
<td>0.2 ± 0.4</td>
</tr>
<tr>
<td>NON-OX (mg/min/kg FFM)</td>
<td>9.9 ± 1.7</td>
<td>9.7 ± 2.0</td>
</tr>
<tr>
<td>FPIR (pmol/L/min)</td>
<td>1559 ± 1330</td>
<td>2122 ± 1464*</td>
</tr>
<tr>
<td>SPIR (pmol/L/min)</td>
<td>2671 ± 2954</td>
<td>2618 ± 602</td>
</tr>
<tr>
<td>AUCtotal (pmol/L/min)*</td>
<td>4469 ± 3905</td>
<td>5032 ± 2985</td>
</tr>
</tbody>
</table>

Data are presented as mean ± SDs. * Significant difference before vs. after bed rest; P<0.05. ** Abbreviations: BP = blood pressure; BMI = body mass index; W/H ratio = waist to hip ratio; FM = fat mass; P = plasma; HDL = high density lipoprotein; LDL = low density lipoprotein; VLDL = very low density lipoprotein.

---

**bed rest impact in carriers of TCF7L2 T-allele**
Data are presented as mean ± SDs. *Significant difference before vs. after bed rest; P<0.05; †Significant difference between the TT/CT and CC groups before bed rest, P<0.05 and ‡P=0.05; †Significant difference between the TT/CT and CC groups after bed rest, P<0.05; +log transformed data.

**Abbreviations:** P = plasma; Ins. stim = insulin-stimulated state; HOMA-IR = homeostasis model assessment- insulin resistance; FFM = free fat mass; GOX = glucose oxidation rate; FOX = fat oxidation rate; NON-OX = non oxidative glucose oxidation rate; D_{i peripheral} = peripheral disposition index; D_{i hepatic} = hepatic disposition index; FPIR = first-phase insulin response; SPIR = second phase insulin response as calculated from the plasma insulin values 10 to 30 minutes after an IVGTT; AUC_total = the total area under the curve.

**Table III** The rate of hepatic insulin action and whole body lipolysis in male study participants according to *TCF7L2* rs7903146 genotype in response to bed rest

<table>
<thead>
<tr>
<th></th>
<th>Before bed rest</th>
<th></th>
<th>After bed rest</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>TT/CT</td>
<td>CC</td>
<td>TT/CT</td>
</tr>
<tr>
<td>rs7903146</td>
<td>21</td>
<td>17</td>
<td>21</td>
</tr>
<tr>
<td>R_a glucose (µmol/min/kg FFM)</td>
<td>10.5 ± 2.3</td>
<td>8.9 ± 3.7</td>
<td>10.7 ± 3.3</td>
</tr>
<tr>
<td>HIR index †</td>
<td>267 ± 156</td>
<td>282 ± 165</td>
<td>310 ± 123</td>
</tr>
<tr>
<td>R_a glycerol (µmol/min/kg FFM) †</td>
<td>3.9 ± 2.8</td>
<td>3.3 ± 2.0</td>
<td>2.7 ± 1.6</td>
</tr>
</tbody>
</table>

Data are presented as mean ± SDs. *Significant difference before vs. after bed rest; P<0.05; †Significant difference between TT/CT and CC group after bed rest, P<0.05; +log transformed data.

**Abbreviations:** R_a glucose = glucose rate of appearance; HIR index = hepatic insulin resistance index; FFM = free fat mass; R_a glycerol = glycerol rate of appearance of glycerol.
FIGURES

Fig. 1

![Diagram showing IVGTT and Hyperinsulinemic euglycemic clamp](image)

Fig. 2

![Graph showing changes in p-insulin and p-C-peptide](image)
Fig. 3

After bed rest

pmol/L

0 min 2 min 4 min 6 min 8 min 10 min

Fig. 4

During bed rest

pmol/L

day 1 day 2 day 3 day 5 day 7 day 9

p-C-peptide

p-insulin